The FDA Extended The Target Action Date For ARA Pharmaceuticals' New Drug Application For Neffy (Intranasal Epinephrine) For Allergic Reactions, Including Anaphylaxis, With An Updated Date Of September 19.
Portfolio Pulse from Benzinga Newsdesk
The FDA has extended the target action date for ARA Pharmaceuticals' New Drug Application for Neffy (intranasal epinephrine) for allergic reactions, including anaphylaxis, to September 19.
June 20, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA extended the target action date for ARA Pharmaceuticals' Neffy New Drug Application, potentially delaying the product's approval and market entry.
The FDA's extension of the target action date for ARA Pharmaceuticals' Neffy New Drug Application may result in a delay in the product's approval and market entry. This could negatively impact the company's stock price in the short term as investors may perceive this as a setback.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100